Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"
Download as PDF
MAY 30, 2018
Scope of exercised Exclusive Option Agreement expanded to include negotiations for IP rights to additional key markers collected in German clinical study, including CSF-tau
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that based upon its review of the clinical data from a German-based clinical study led by Leipzig University's (Leipzig) Dr. Thomas Arendt, the Company has exercised its Exclusive Option with Leipzig to negotiate license rights to Alzheimer's blood diagnostic "LymPro Test 2.0," which compares traditional LymPro Test results with those of amyloid PET imaging for the diagnosis of Alzheimer's disease. Amarantus and Leipzig have agreed to expand the scope of license negotiations to include additional key markers collected during the clinical study, including CSF-tau.
"LymPro holds significant promise as a solution to one of the key areas of Alzheimer's research: the use of a blood-based biomarker for the early detection of Alzheimer's, either at the pre-symptomatic stage or mild cognitive impairment stage, in patients likely to progress to full dementia of the Alzheimer's-type," said Dr. Michael Ropacki, Chief Medical Advisor for LymPro.
Leipzig University has completed a clinical study comparing LymPro's ability to distinguish dementia of the Alzheimer's-type from other types of dementia, as diagnosed using clinical assessments and biological markers (including amyloid PET imaging and CSF-tau). Upon closing a final license agreement for Leipzig's IP Rights related to LymPro Test 2.0, as well as related collaboration agreements, Amarantus will collaborate with Leipzig on a confirmatory clinical study that is already enrolling in Germany under Dr. Arendt's supervision.
AAIC 2015 Poster Presentation of LymPro Test LP-002 Clinical Data
Amarantus Alzheimer's Diagnostics Scientific Advisory Board
LymPro Test CLIA Validation complete
Dr. Ropacki Appointed Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test
Download as PDF
MAY 30, 2018
Scope of exercised Exclusive Option Agreement expanded to include negotiations for IP rights to additional key markers collected in German clinical study, including CSF-tau
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that based upon its review of the clinical data from a German-based clinical study led by Leipzig University's (Leipzig) Dr. Thomas Arendt, the Company has exercised its Exclusive Option with Leipzig to negotiate license rights to Alzheimer's blood diagnostic "LymPro Test 2.0," which compares traditional LymPro Test results with those of amyloid PET imaging for the diagnosis of Alzheimer's disease. Amarantus and Leipzig have agreed to expand the scope of license negotiations to include additional key markers collected during the clinical study, including CSF-tau.
"LymPro holds significant promise as a solution to one of the key areas of Alzheimer's research: the use of a blood-based biomarker for the early detection of Alzheimer's, either at the pre-symptomatic stage or mild cognitive impairment stage, in patients likely to progress to full dementia of the Alzheimer's-type," said Dr. Michael Ropacki, Chief Medical Advisor for LymPro.
Leipzig University has completed a clinical study comparing LymPro's ability to distinguish dementia of the Alzheimer's-type from other types of dementia, as diagnosed using clinical assessments and biological markers (including amyloid PET imaging and CSF-tau). Upon closing a final license agreement for Leipzig's IP Rights related to LymPro Test 2.0, as well as related collaboration agreements, Amarantus will collaborate with Leipzig on a confirmatory clinical study that is already enrolling in Germany under Dr. Arendt's supervision.
AAIC 2015 Poster Presentation of LymPro Test LP-002 Clinical Data
Amarantus Alzheimer's Diagnostics Scientific Advisory Board
LymPro Test CLIA Validation complete
Dr. Ropacki Appointed Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test
11
